GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc.
08 Diciembre 2008 - 8:11AM
PR Newswire (US)
LONDON, and PHILADELPHIA, Dec. 8 /PRNewswire-FirstCall/ --
GlaxoSmithKline (LSE/NYSE: GSK) announced today that it has
extended its previously announced tender offer to purchase all of
the outstanding shares of common stock of Genelabs Technologies,
Inc. (NASDAQ:GNLB), for $1.30 in cash per share without interest
and less any required withholding taxes, until 12:00 midnight EST
on Friday, December 12, 2008, unless the tender offer is further
extended. The tender offer was originally scheduled to expire at
12:00 midnight EST on Wednesday, December 10, 2008. GSK has
extended the tender offer in connection with the addition of
SmithKline Beecham Corporation, a wholly-owned subsidiary of GSK,
as a bidder, as defined in the Securities Exchange Act of 1934, as
amended, with respect to the tender offer. As of 5 p.m., EST, on
December 5, 2008, approximately 3,466,063 shares of Genelabs common
stock have been tendered and not withdrawn pursuant to the tender
offer, representing approximately 7.8% of the outstanding shares of
Genelabs common stock on a fully diluted basis. The tender offer
was commenced on November 12, 2008 pursuant to a previously
announced Agreement and Plan of Merger dated October 29, 2008 among
Genelabs, Gemstone Acquisition Corporation and SmithKline Beecham
Corporation. All other terms and conditions of the tender offer
remain the same, including the condition that, at the expiration of
the offer, there have been validly tendered and not withdrawn that
number of shares which, together with the number of shares, if any,
then beneficially owned by GSK and its wholly-owned subsidiaries,
constitutes at least 90 percent of the total number of the then
outstanding Genelabs shares on a fully diluted basis. The terms and
conditions of the tender offer are set forth in the Offer to
Purchase dated November 12, 2008, and as subsequently amended.
Questions and requests for assistance may be directed to the
Information Agent for the offer, MacKenzie Partners, Inc., at (212)
929-5500 or (800) 322- 2885 (toll free). GlaxoSmithKline -- one of
the world's leading research-based pharmaceutical and healthcare
companies -- is committed to improving the quality of human life by
enabling people to do more, feel better and live longer. Important
information This press release is neither an offer to purchase nor
a solicitation of an offer to sell shares of Genelabs. The
solicitation and the tender offer to buy shares of Genelabs is only
being made pursuant to the Offer to Purchase and related materials
that GSK, SmithKline Beecham Corporation and Gemstone Acquisition
Corporation filed with the Securities and Exchange Commission (SEC)
on November 12, 2008 and as subsequently amended. Investors and
security holders should read these materials carefully because they
contain important information, including the terms and conditions
of the tender offer. Investors and security holders may obtain free
copies of the materials filed with the SEC by GSK and Genelabs
relating to the tender offer through the web site maintained by the
SEC at http://www.sec.gov/. In addition, investors and security
holders may obtain free copies of these materials by contacting the
Information Agent for the offer, MacKenzie Partners, Inc., at (212)
929-5500 or (800) 322-2885 (toll free) or the Investor Relations
departments of GSK or Genelabs. Registered in England & Wales:
No. 3888792 Registered Office: 980 Great West Road Brentford,
Middlesex TW8 9GS DATASOURCE: GlaxoSmithKline CONTACT: UK Media:
Philip Thomson, Alice Hunt, Gwenan White, or Stephen Rea, all at
(020) 8047 5502; or for US Media: Nancy Pekarek or Mary Anne Rhyne,
both at 919-483-2839, or Sarah Alspach, +1-215-751 7709; or for
European Analyst-Investor: David Mawdsley, (020) 8047 5564, or
Sally Ferguson, (020) 8047 5543, or Gary Davies, (020) 8047 5503;
or for US Analyst-Investor: Tom Curry, +1-215-751-5419, or Jen
Hill, +1-215-751-7002, all of GlaxoSmithKline Web site:
http://www.gsk.com/ Company News On-Call:
http://www.prnewswire.com/comp/801350.html
Copyright
Genelabs (NASDAQ:GNLB)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Genelabs (NASDAQ:GNLB)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024